The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Now, a new study may provide some clarity. A team led by researchers at Princeton University and the Simons Foundation has ...

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial ...

European shares experienced gains, poised for their largest weekly increase in 12 weeks. This rise is fueled by U.S.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Youth ages 1 to 18 consumed more calories from UPFs than adults: 61.9% of calories consumed versus 53% for adults.

Chai Discovery, a company that builds frontier artificial intelligence models to predict and reprogram interactions between ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...

Several studies have found patients taking GLP-1 medications like Wegovy and Mounjaro regain weight, sparking fresh health advice from experts.

HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a ...